The Harmonic™ trial is a Phase 2 multi-center study focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022. In a previous Phase 3 ...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional details and clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results